Management of patients refractory to platelet transfusion

Journal of Infusion Nursing

Volumn 30, Issue 4, 2007, Pages 220-225

  Chockalingam, Porselvi ^a,b   Sacher, Ronald A ^a,c,d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b KASTURBA MEDICAL COLLEGE   (India)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; THROMBOCYTE ANTIBODY;

ALLOIMMUNIZATION; ANTIGEN SPECIFICITY; BLOOD DONOR; HUMAN; IMMUNOGENICITY; LEUKAPHERESIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECIPIENT; REVIEW; THROMBOCYTE TRANSFUSION; ULTRAVIOLET B RADIATION;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; BODY SURFACE AREA; CAUSALITY; HISTOCOMPATIBILITY TESTING; HUMANS; ISOANTIBODIES; NURSING ASSESSMENT; PATIENT SELECTION; PLATELET COUNT; PLATELET TRANSFUSION; PRACTICE GUIDELINES; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT FAILURE;

EID: 34547670616     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000281531.97183.c0     Document Type: Review

References (29)

1. Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang. 1999;76:1-13.
2. Pisciotto PT, Benson K, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion. 1995;35:498-502.
3. Eikenboom JC, van Wordragen R, Brand A. Compliance with prophylactic platelet transfusion trigger in haematological patients. Transfus Med. 2005;15:45-48.
4. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18:153-167.
5. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519-1538.
6. Strauss RG. Pretransfusion trigger platelet counts and dose for prophylactic platelet transfusions. Curr Opin Hematol. 2005;12:499-502.
7. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev. 2004;18:149-165.
8. Kekomaki R. Use of HLA- and HPA-matched platelets in alloimmunized patients. Vox Sang. 1998;74(Suppl 2):359-363.
9. O'Connell B, Lee EJ, Schiffer CA. The value of 10-minute post-transfusion platelet counts. Transfusion. 1988;28:66-67.
10. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions: The trial to reduce alloimmunization to platelets study group. N Engl J Med. 1997;337:1861-1869.
11. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood. 1993;81:3428-3434.
12. Fabris F, Soini B, Sartori R, Randi ML, Luzzatto G, Girolami A. Clinical and laboratory factors that affect the posttransfusion platelet increment. Transfus Sci. 2000;23:63-68.
13. Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol. 2002;9:516-520.
14. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991;77:201-205.
15. Sniecinski I, Jean JS, Nowicki B. Preparation of leukocyte-poor platelets by filtration. J Clin Apher. 1989;5:7-11.
16. Santoso S, Kiefel V. Human platelet alloantigens. Wien Klin Wochenschr. 2001;113:806-813.
17. Sandler SG. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions. Haematologia (Budap). 1998;29:1-11.
18. Engelfriet CP, Reesink HW, Aster RH, et al. Management of alloimmunized, refractory patients in need of platelet transfusions. Vox Sang. 1997;73:191-198.
19. Sanz C, Freire C, Alcorta I, Ordinas A, Pereira A. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion. 2001;41:762-765.
20. Dan ME, Schiffer CA. Strategies for managing refractoriness to platelet transfusions. Curr Hematol Rep. 2003;2:158-164.
21. Slichter SJ. Algorithm for managing the platelet refractory patient. J Clin Apher. 1997;12:4-9.
22. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000;14:180-196.
23. Choudhry VP. Platelet therapy. Indian J Pediatr. 2002;69:779-783.
24. Sacher RA, Kickler TS, Schiffer CA, et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med. 2003;127:409-414.
25. Bai CM, Zou XY, Zhao YQ, Han SM, Shan YD, Thrombopoietin Clinical Trial Cooperation Group. The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia. Zhonghua Yi Xue Za Zhi. 2004;84:397-400.
26. Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003;21:3158-3167.
27. Zhao Y, Jiang J, Jiao L. Clinical tolerance test of recombinant human thrombopoietin. Zhonghua Yi Xue Za Zhi. 2001;81:1508-1511.
28. Kickler TS. The challenge of platelet alloimmunization: Management and prevention. Transfus Med Rev. 1990;4:8-18.
29. Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev. 1998;12:258-270.